Dai, H., Sun, X., Wei, Y., Guo, X., Wang, C., Jia, H., Wu, J., Chen, X., Qiao, J., Zhang, C., Li, L., Yu, J., Li, P., Yuan, P., Sun, Y., Lu, P., Wang, X., Xia, Q., Lu, Z., Liu, Z. (2026). Delayed serplulimab combined with nab-paclitaxel and epirubicin in high-risk, early HR+/HER2− breast cancer (HELEN-B 018): A multicenter, single-arm, phase 2 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.609